Literature DB >> 21796624

Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis.

Davide Rossi1, Valeria Spina, Francesco Forconi, Daniela Capello, Marco Fangazio, Silvia Rasi, Maurizio Martini, Valter Gattei, Antonio Ramponi, Luigi M Larocca, Francesco Bertoni, Gianluca Gaidano.   

Abstract

Richter syndrome (RS) represents the transformation of chronic lymphocytic leukemia to aggressive lymphoma. We explored intraclonal diversification (ID) of immunoglobulin genes in order to (i) follow the evolutionary history of the RS clone (ii) compare the role of ID in clonally related RS vs. clonally unrelated cases. Most (10/11, 90.9%) clonally related RS stem from the predominant clone observed at CLL diagnosis. One single RS had a transformation pattern compatible with sequential evolution from a secondary CLL subclone. Once RS transformation had occurred, all secondary CLL subclones disappeared and were substituted by the dominant RS clone with its own descendants. These observations suggest that genetic lesions associated with RS transformation are acquired by a cell belonging to the original CLL clone, rather than being progressively accumulated by later CLL subclones. Accordingly, most (9/11, 81.1%) clonally related RS harbored a genetic lesion disrupting TP53 that was already present, though at subclonal levels, in 5/11 (45.5%) samples of the paired CLL phase. A fraction of clonally related RS switched off ID (4/11, 36.4%) or reduced the levels of ID (5/11, 45.4%) at transformation. Conversely, all clonally unrelated RS harbored ID and were characterized by a significantly higher mutation frequency compared to clonally related RS (median: 1.18 × 10(-3) vs. 0.13 × 10(-3); p =0.002). These data indicate that (i) clonally related RS stems from a cell that is already present within the initial CLL clone and (ii) clonally unrelated and clonally related RS are biologically distinct disorders also in terms of antigen affinity maturation.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21796624     DOI: 10.1002/ijc.26322

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia.

Authors:  Jennifer R Brown; Megan Hanna; Bethany Tesar; Lillian Werner; Nathalie Pochet; John M Asara; Yaoyu E Wang; Paola Dal Cin; Stacey M Fernandes; Christina Thompson; Laura Macconaill; Catherine J Wu; Yves Van de Peer; Mick Correll; Aviv Regev; Donna Neuberg; Arnold S Freedman
Journal:  Clin Cancer Res       Date:  2012-05-23       Impact factor: 12.531

Review 2.  Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Authors:  Mohamed A Kharfan-Dabaja; Ambuj Kumar; Mehdi Hamadani; Stephan Stilgenbauer; Paolo Ghia; Claudio Anasetti; Peter Dreger; Emili Montserrat; Miguel-Angel Perales; Edwin P Alyea; Farrukh T Awan; Ernesto Ayala; Jacqueline C Barrientos; Jennifer R Brown; Januario E Castro; Richard R Furman; John Gribben; Brian T Hill; Mohamad Mohty; Carol Moreno; Susan O'Brien; Steven Z Pavletic; Javier Pinilla-Ibarz; Nishitha M Reddy; Mohamed Sorror; Christopher Bredeson; Paul Carpenter; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-19       Impact factor: 5.742

Review 3.  Molecular pathogenesis of chronic lymphocytic leukemia.

Authors:  Gianluca Gaidano; Robin Foà; Riccardo Dalla-Favera
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

4.  Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.

Authors:  Ohad Benjamini; Preetesh Jain; Long Trinh; Wei Qiao; Sara S Strom; Susan Lerner; Xuemei Wang; Jan Burger; Alessandra Ferrajoli; Hagop Kantarjian; Susan O'Brien; William Wierda; Zeev Estrov; Michael Keating
Journal:  Leuk Lymphoma       Date:  2014-11-19

Review 5.  The genomic landscape of chronic lymphocytic leukemia: clinical implications.

Authors:  Víctor Quesada; Andrew J Ramsay; David Rodríguez; Xose S Puente; Elías Campo; Carlos López-Otín
Journal:  BMC Med       Date:  2013-05-09       Impact factor: 8.775

6.  Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.

Authors:  Giulia Fabbri; Hossein Khiabanian; Antony B Holmes; Jiguang Wang; Monica Messina; Charles G Mullighan; Laura Pasqualucci; Raul Rabadan; Riccardo Dalla-Favera
Journal:  J Exp Med       Date:  2013-10-14       Impact factor: 14.307

7.  Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.

Authors:  Paul Yeh; Tane Hunter; Devbarna Sinha; Sarah Ftouni; Elise Wallach; Damian Jiang; Yih-Chih Chan; Stephen Q Wong; Maria Joao Silva; Ravikiran Vedururu; Kenneth Doig; Enid Lam; Gisela Mir Arnau; Timothy Semple; Meaghan Wall; Andjelija Zivanovic; Rishu Agarwal; Pasquale Petrone; Kate Jones; David Westerman; Piers Blombery; John F Seymour; Anthony T Papenfuss; Mark A Dawson; Constantine S Tam; Sarah-Jane Dawson
Journal:  Nat Commun       Date:  2017-03-17       Impact factor: 14.919

8.  The Occurrence of Richter's Syndrome during Treatment with Obinutuzumab and Chlorambucil.

Authors:  Teng Fong Ng; Benedict Carnley; Celia Green; Dominic Spagnolo; Michael F Leahy
Journal:  Case Rep Hematol       Date:  2020-07-16

9.  Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.

Authors:  Jenny Klintman; Niamh Appleby; Basile Stamatopoulos; Katie Ridout; Toby A Eyre; Pauline Robbe; Laura Lopez Pascua; Samantha J L Knight; Helene Dreau; Maite Cabes; Niko Popitsch; Mats Ehinger; Jose I Martín-Subero; Elías Campo; Robert Månsson; Davide Rossi; Jenny C Taylor; Dimitrios V Vavoulis; Anna Schuh
Journal:  Blood       Date:  2021-05-20       Impact factor: 22.113

10.  Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients.

Authors:  Julie Morscio; Emilie Bittoun; Nathalie Volders; Eveline Lurquin; Iwona Wlodarska; Olivier Gheysens; Peter Vandenberghe; Gregor Verhoef; Philippe Demaerel; Daan Dierickx; Xavier Sagaert; Ann Janssens; Thomas Tousseyn
Journal:  J Hematop       Date:  2016-05-21       Impact factor: 0.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.